International clinical trial updates to look out for in 2025
The Motor Neurone Disease Association has highlighted four trials expected to report results in 2025: AP-101, ambroxol, masitinib and metformin. Phase 3 trials of PrimeC and CNM-Au8 are also expected to begin, with possible accelerated-approval applications planned for PrimeC in Canada and CNM-Au8 in the United States.
Why this matters
These studies could provide evidence about potential treatments for specific groups of people with MND, including those with SOD1 or C9orf72 gene changes. However, the trials have not yet established that these treatments work, and this update does not change treatment for anyone now.
Limitations and context
This information comes from an organisational research blog describing anticipated trial milestones, not from trial results or a peer-reviewed research paper. The stated dates and regulatory plans are expectations, and the treatments still require evidence from their relevant trials. The source does not provide detailed participant numbers or full trial results for the studies expected to report.